TP53 and acute lymphoblastic leukemia: Considering the impairment of p53-dependent apoptosis by VEN in MLLr BCP-ALL, we selected AUR, a drug that had been reported to exert cytotoxic effects independently of p53 [24], for the combination treatment with VEN.